To amend title XVIII of the Social Security Act to apply prescription drug inflation rebates to drugs furnished in the commercial market and to change the base year for rebate calculations.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill requires application of prescription drug inflation rebates to drugs furnished in the commercial market; change of base year for rebate calculations Section 1847A(i) of the Social Security Act (42 U.S.C. It relies on definition changes, reporting requirements, compliance mandates, and exemptions. The main policy areas are Healthcare Consumers and Healthcare.
Who Benefits and How
Patients and health care consumers affected by the bill could face lower compliance burdens.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties and Public beneficiaries or protected communities affected by the clause could face increased risk.
Key Provisions
- Requires application of prescription drug inflation rebates to drugs furnished in the commercial market; change of base year for rebate calculations Section 1847A(i) of the Social Security Act (42 U.S.C.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill requires application of prescription drug inflation rebates to drugs furnished in the commercial market; change of base year for rebate calculations Section 1847A(i) of the Social Security Act (42 U.S.C.
Key Policy Areas
Healthcare Consumers, Healthcare
Primary Purpose
The bill requires application of prescription drug inflation rebates to drugs furnished in the commercial market; change of base year for rebate calculations Section 1847A(i) of the Social Security Act (42 U.S.C.
Policy Domains
Whole bill
Identified Gains
- Patients and health care consumers affected by the bill
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
- Public beneficiaries or protected communities affected by the clause
Sponsors
Legislative Progress
IntroducedMs. Cortez Masto (for herself, Ms. Klobuchar, Mr. Reed, Ms. …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology